HepaRegeniX GmbH
PrivateLast Round
Series C
Apr 15, 2025
Total Funding Raised
$70.44M
Company Overview
HepaRegeniX GmbH is a biotechnology company developing novel regenerative therapies for the treatment of acute and chronic liver diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
HepaRegeniX GmbH Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
HepaRegeniX GmbH Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Apr 15, 2025 | ||||
| Series C | Jul 10, 2024 | ||||
| Series B | Jan 21, 2020 | ||||
| Series A | Jan 5, 2017 |
Key People
Founding team and executive leadership
HepaRegeniX GmbH Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boehringer Ingelheim | Series B, Series C, Series A |
| Ascenion | Series B, Series C, Series A |
| Vesalius Biocapital Partners | Series C |
| Novo Holdings | Series B, Series C, Series A |
| Boehringer Ingelheim Venture Fund | Series B, Series C, Series A |
| Wellington Partners | Series C |
| High-Tech Gründerfonds | Series B, Series C, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 11, 2025
HRX-233 targets kinase inhibitor resistance in KRAS-driven tumours.
- May 8, 2025
Presented development updates and clinical data for HRX-215 at EASL Congress 2025.
HepaRegeniX GmbH Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about HepaRegeniX GmbH's valuation, stock price, and market status.